Loading...
•
Mar 31, 2024
Iovance Q1 2024 Earnings Report
Iovance reported first quarter 2024 financial results and corporate updates following FDA approval and strong start for the U.S. commercial launch of Amtagvi™.
Key Takeaways
Iovance Biotherapeutics reported a net loss of $113.0 million for the first quarter of 2024, with revenue of $0.7 million from Proleukin sales. The company highlighted the strong initial demand for Amtagvi, with over 100 patients enrolled across more than 40 authorized treatment centers.
Amtagvi U.S. launch is off to a strong start following FDA approval.
Over 100 patients have enrolled for Amtagvi therapy across more than 40 authorized treatment centers.
Amtagvi regulatory submissions are on track in the EU, UK, and Canada for 2024.
Iovance is ramping up the U.S. launch throughout 2024 with additional ATCs.
Forward Guidance
Iovance anticipates continued strong launch momentum for Amtagvi in the U.S. throughout 2024 and is progressing with regulatory submissions in Europe and Canada.
Positive Outlook
- Strong initial demand for Amtagvi is expected to continue.
- Ramping up the U.S. launch with the authorization of additional ATCs.
- Amtagvi regulatory submissions are on track in the EU, UK, and Canada in 2024.
- Well positioned to remain the global leader in innovating, developing, and delivering TIL cell therapy for patients with cancer.
- Continue to execute across broad clinical pipeline.
Challenges Ahead
- Future competitive or other market factors may adversely affect the commercial potential for Amtagvi or Proleukin.
- The risk that the EMA or other ex-U.S. regulatory authorities may not approve or may delay approval for our marketing authorization application submission for lifileucel in metastatic melanoma.
- The risk whether the number of patients treated and/or ATCs is an appropriate measure of commercial success and/or recognized revenue.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...